Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
November 13 2024 - 4:01PM
Business Wire
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced
that Sravan Emany, Chief Operating Officer and Chief Financial
Officer, will participate in a fireside chat at the Jefferies
London Healthcare Conference on Wednesday, November 20, 2024 at
7:30 a.m. GT at the Waldorf Hilton in London.
A live webcast of Ironwood’s fireside chat will be accessible
through the Investors section of the company’s website at
www.ironwoodpharma.com. A replay of the webcast will be available
on Ironwood’s website for 1 year following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap
600® company, is a leading gastrointestinal (GI) healthcare company
on a mission to advance the treatment of GI diseases and redefine
the standard of care for GI patients. We are pioneers in the
development of LINZESS® (linaclotide), the U.S. branded
prescription market leader for adults with irritable bowel syndrome
with constipation (IBS-C) or chronic idiopathic constipation (CIC).
LINZESS is also approved for the treatment of functional
constipation in pediatric patients ages 6-17 years-old. Ironwood is
also advancing apraglutide, a next-generation, long-acting
synthetic GLP-2 analog being developed for rare gastrointestinal
diseases, including short bowel syndrome with intestinal failure
(SBS-IF), as well as several earlier stage assets. Building upon
our history of GI innovation, we keep patients at the heart of our
R&D and commercialization efforts to reduce the burden of GI
diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in
Boston, Massachusetts, with a site in Basel, Switzerland.
We routinely post information that may be important to investors
on our website at www.ironwoodpharma.com. In addition, follow us on
X and on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241113193170/en/
Investors: Greg Martini, 617-374-5230
gmartini@ironwoodpharma.com
Matt Roache, 617-621-8395 mroache@ironwoodpharma.com
Media: Beth Calitri, 978-417-2031
bcalitri@ironwoodpharma.com
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Nov 2024 to Dec 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Dec 2023 to Dec 2024